124458-16-8

Basic information

• Product Name: 2-[2-(2-ANILINO-1,3-THIAZOL-4-YL)ETHYL]-1H-ISOINDOLE-1,3(2H)-DIONE
• Synonyms: 2-[2-(2-ANILINO-1,3-THIAZOL-4-YL)ETHYL]-1H-ISOINDOLE-1,3(2H)-DIONE;2-{2-[2-(phenylamino)-1,3-thiazol-4-yl]ethyl}-2,3-dihydro-1H-isoindole-1,3-dione
• CAS NO: 124458-16-8
• Molecular Formula: C₁₉H₁₅N₃O₂S
• Molecular Weight: 349.41
• Mol File: 124458-16-8.mol

Chemical Properties

• Boiling Point: 545.9±52.0 °C(Predicted)
• Appearance: /
• Density: 1.399±0.06 g/cm3(Predicted)
• PKA: 4.24±0.10(Predicted)
• CAS DataBase Reference: 2-[2-(2-ANILINO-1,3-THIAZOL-4-YL)ETHYL]-1H-ISOINDOLE-1,3(2H)-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-(2-ANILINO-1,3-THIAZOL-4-YL)ETHYL]-1H-ISOINDOLE-1,3(2H)-DIONE(124458-16-8)
• EPA Substance Registry System: 2-[2-(2-ANILINO-1,3-THIAZOL-4-YL)ETHYL]-1H-ISOINDOLE-1,3(2H)-DIONE(124458-16-8)

Safety Data

• Hazardous Substances Data: 124458-16-8(Hazardous Substances Data)

Upstream product

• 62-53-3 aniline 
• 4921-82-8 1-benzoyl-3-phenylthiourea 
• 51132-00-4 2-(4-bromo-3-oxobutyl)isoindoline-1,3-dione 
• 103-85-5 monophenylthiourea 

Downstream Products

• 124458-17-9 2-[2-(Phenylamino)thiazol-4-yl]ethanamine 

Relevant articles and documents

Histamine H1 receptor ligands - Part II. Synthesis and in vitro pharmacology of 2-[2-(phenylamino)thiazol-4-yl]ethanamine and 2-(2-benzhydrylthiazol-4-yl)ethanamine derivatives

New 2-[2-(phenylamino)thiazol-4-yl]ethanamine and 2-(2-benzhydrylthiazol-4-yl)ethanamine derivatives were prepared and tested in vitro as H1 receptor antagonists. The compounds with 2-phenylamino substitution with meta-halide substituents at the phenyl ring, showed weak H1-antagonistic activity (pA2: 4.62-5.04) and this activity was completely lost in the case of meta-methyl substituent (pA2 : 4). When the phenylamino group was replaced by benzhydryl groups of classic antihistamines, the resulting compounds exhibited slightly improved H1-antagonistic activity (at the meta-position pA2: 6.38-6.15; at the para-position pA2: 6.04-5.87).